CEO Sam Cobb provides an update to the Morgans Network

AdAlta CEO Sam Cobb met with Morgans Senior Analyst, Scott Power, in August 2018 to provide an introduction to AdAlta, an update on the progress of improved lead candidate, AD-214 and some background on Idiopathic Pulmonary Fibrosis, a lung condition in desperate need of new treatment options for which AdAlta is developing AD-214. The interview can be viewed below and AdAlta’s latest company presentation can be foundĀ here.